Catalyst Pharma Partners Win Extension to Regain Compliance with NASDAQ Listing Requirements
June 25, 2013 at 11:36 AM EDT
Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX ), a specialty pharmaceutical company focused on the development and commercialization of novel prescription drugs targeting rare (orphan) neuromuscular and neurological diseases, announced today that it has received a letter from The Nasdaq Stock Market ("Nasdaq") on June 25, 2013, granting a 180-day extension period in which to
